Changes in markers of coagulological blood analysis in relation to markers of systemic inflammation in patients with sarcoidosis after COVID-19 during treatment

Objective. To evaluate changes in markers of coagulological blood analysis in relation to markers of systemic inflammation in patients with sarcoidosis after COVID-19 during treatment.

Material and methods. The study included 20 patients who were divided into 2 groups: main group (n=10) – patients with newly diagnosed intracoracic lymph nodes sarcoidosis and lung sarcoidosis in the active phase who suffered COVID-19; control group (n=10) – patients with newly diagnosed intracoracic lymph nodes sarcoidosis and lung sarcoidosis in the active phase without COVID-19 in the anamnesis. Biochemical studies were carried out at two control points: at the admission of patients to the clinic and in dynamics after 2 weeks of treatment. The following parameters were evaluated: activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, thrombin time (TT), antithrombin III (ATIII), D-dimer, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

Results. Analysis of the study results showed that before the start of treatment in the mane group, a decrease in APTT levels was significantly more common compared to the control group (p = 0,00001), an increase in fibrinogen levels (p = 0,0006) and D-dimer (p = 0,00003). After 2 weeks of treatment, the number of patients in the mane group with a hypercoagulation shift remained the same, and there were no such patients in the control group. Analysis of the CRP and ESR markers showed that before the start of treatment, patients with systemic inflammation were found in both groups. After 2 weeks of treatment in both groups, the number of patients with both increased CRP, and with increased ESR.

Conclusion. Before the start of treatment, patients with newly diagnosed intracoracic lymph nodes sarcoidosis and lung sarcoidosis in the active phase with a history of COVID-19 were significantly more likely to have a hypercoagulation shift, which was associated with the presence of pronounced systemic inflammation in these patients. After 2 weeks of treatment, the number of patients with a hypercoagulable shift remained at the same level, despite a decrease in the incidence of patients with elevated values of systemic inflammation markers, which indicated that in addition to inflammatory reactions, changes in the vascular endothelium probably played a role in the development of hypercoagulable disorders.